Unity Biotechnology, Inc.

OTCPK:UNBX Stock Report

Market Cap: US$1.8m

Unity Biotechnology Future Growth

Future criteria checks 2/6

Unity Biotechnology is forecast to grow revenue at 42.1% per annum.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth23.3%
Revenue growth rate42.1%
Future return on equity-37.12%
Analyst coverage

Low

Last updated18 Jul 2025

Recent future growth updates

Recent updates

Is Unity Biotechnology (NASDAQ:UBX) In A Good Position To Invest In Growth?

Nov 05
Is Unity Biotechnology (NASDAQ:UBX) In A Good Position To Invest In Growth?

Will Unity Biotechnology (NASDAQ:UBX) Spend Its Cash Wisely?

Jul 12
Will Unity Biotechnology (NASDAQ:UBX) Spend Its Cash Wisely?

Here's Why We're A Bit Worried About Unity Biotechnology's (NASDAQ:UBX) Cash Burn Situation

Mar 05
Here's Why We're A Bit Worried About Unity Biotechnology's (NASDAQ:UBX) Cash Burn Situation

Companies Like Unity Biotechnology (NASDAQ:UBX) Could Be Quite Risky

Nov 18
Companies Like Unity Biotechnology (NASDAQ:UBX) Could Be Quite Risky

UNITY Biotechnology falls 7% on reverse stock split

Oct 19

Unity Biotechnology cuts stock sales agreement in half to $25M

Aug 19

Unity Biotechnology GAAP EPS of -$0.19 beats by $0.10, revenue of $0.24M

Aug 12

A Look At Unity's UBX1325 Phase 1 Results

Jul 26

Trade Alert: The Co-Founder Of Unity Biotechnology, Inc. (NASDAQ:UBX), Nathaniel David, Has Sold Some Shares Recently

Dec 22
Trade Alert: The Co-Founder Of Unity Biotechnology, Inc. (NASDAQ:UBX), Nathaniel David, Has Sold Some Shares Recently

Earnings and Revenue Growth Forecasts

OTCPK:UNBX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202730N/AN/AN/A2
12/31/202612N/AN/AN/A2
12/31/2025N/AN/AN/AN/A2
3/31/2025N/A-28-22-22N/A
12/31/2024N/A-26-21-21N/A
9/30/2024N/A-22-23-23N/A
6/30/2024N/A-30-24-24N/A
3/31/2024N/A-40-31-31N/A
12/31/2023N/A-40-37-37N/A
9/30/2023N/A-34-41-41N/A
6/30/2023N/A-33-45-45N/A
3/31/20230-31-49-49N/A
12/31/20220-44-53-52N/A
9/30/20225-56-46-46N/A
6/30/20225-59-47-46N/A
3/31/20225-64-45-45N/A
12/31/20215-61-45-45N/A
9/30/2021N/A-70-57-57N/A
6/30/2021N/A-81-63-62N/A
3/31/2021N/A-82-69-68N/A
12/31/2020N/A-94-79-78N/A
9/30/2020N/A-92-78-77N/A
6/30/2020N/A-86-78-77N/A
3/31/2020N/A-91-78-77N/A
12/31/2019N/A-82-74-72N/A
9/30/2019N/A-86-71-70N/A
6/30/2019N/A-83-68-67N/A
3/31/2019N/A-79-67-65N/A
12/31/2018N/A-76N/A-57N/A
9/30/20181-67N/A-55N/A
6/30/20181-60N/A-51N/A
3/31/20181-52N/A-42N/A
12/31/20171-45N/A-38N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if UNBX's forecast earnings growth is above the savings rate (2.9%).

Earnings vs Market: Insufficient data to determine if UNBX's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if UNBX's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: UNBX's revenue (42.1% per year) is forecast to grow faster than the US market (9% per year).

High Growth Revenue: UNBX's revenue (42.1% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: UNBX is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/28 13:53
End of Day Share Price 2025/07/25 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Unity Biotechnology, Inc. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yigal NochomovitzCitigroup Inc
Andrew FeinH.C. Wainwright & Co.
Matthew CaufieldH.C. Wainwright & Co.